Details

Autor(en) / Beteiligte

• Montanari, Micaela
• Rossetti, Sabrina
• Cavaliere, Carla
• D'Aniello, Carmine
• Malzone, Maria Gabriella
• Vanacore, Daniela
• Di Franco, Rossella
• La Mantia, Elvira
• Iovane, Gelsomina
• Piscitelli, Raffaele
• Muscariello, Raffaele
• Berretta, Massimiliano
• Perdonà, Sisto
• Muto, Paolo
• Botti, Gerardo
• Bianchi, Attilio Antonio Montano
• Veneziani, Bianca Maria
• Facchini, Gaetano

Titel

Epithelial-mesenchymal transition in prostate cancer: an overview

Ist Teil von

• Oncotarget, 2017-05, Vol.8 (21), p.35376-35389

Ort / Verlag

United States: Impact Journals LLC

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Prostate cancer is a main urological disease associated with significant morbidity and mortality. Radical prostatectomy and radiotherapy are potentially curative for localized prostate cancer, while androgen deprivation therapy is the initial systemic therapy for metastatic prostate disease. However, despite temporary response, most patients relapse and evolve into castration resistant cancer.Epithelial-mesenchymal transition (EMT) is a complex gradual process that occurs during embryonic development and/or tumor progression. During this process, cells lose their epithelial characteristics and acquire mesenchymal features. Increasing evidences indicate that EMT promotes prostate cancer metastatic progression and it is closely correlated with increased stemness and drug resistance.In this review, we discuss the main molecular events that directly or indirectly govern the EMT program in prostate cancer, in order to better define the role and the mechanisms underlying this process in prostate cancer progression and therapeutic resistance.